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Background
Myocarditis is an uncommon, but fearsome compli-
cation of immune checkpoint inhibitors (ICPis) be-
cause it may result in life-threatening heart failure,
cardiogenic shock, and arrhythmias.1-4 Among more
than 20,000 patients treated with nivolumab and/or
ipilimumab until April 2016 and included in a safety
database of Bristol-Myers Squibb regardless of ad-
verse events (AEs), 0.09% experienced myocarditis
and less than 0.03% experienced fatal myocarditis.2
Of all 964 patients at the Massachusetts General
Hospital who received ICPis between November 2013
and July 2017, 1.14% developed myocarditis and
0.52% had major cardiovascular AEs.3 According to
a recent study, 122 cases of ICPi-related myocarditis
were recorded since 2013 in VigiBase, the WHO da-
tabase of individual patient safety reports.4 Classiﬁ-
cation was severe in 84%, and death was more
frequent with combination than with single immune
therapy (66% v 40%).
The analysis of VigiBase conﬁrmed that myocarditis is
strongly associatedwith ICPis because reports of this AE
between 2008 and 2018 were 11-fold higher for ICPis
than for all drugs.4 Furthermore, the analysis showed
that the prevalence of myocarditis after ICPis has
steadily increased over the years, which suggests that
the burden of this complication is growing. This trend
may be ascribed to various factors and is predicted to
become even stronger in the near future. First, ICPis are
being prescribed to a progressively larger population,
which increases the absolute number of individuals who
are expected to have myocarditis, even if the percent of
the total treated patients remains low.5 Moreover, it is
conceivable that myocarditis was missed in a non-
negligible number of patients during the initial experi-
ence with ICPis because myocarditis often has an in-
sidious clinical presentation or a relatively benign,
indolent course and, therefore, may not be recognized.
Now, it is known that ICPis can cause myocarditis, and
more attention is being paid to this AE than previously;
thus, atypical or smoldering forms of the disease also
are likely to be diagnosed.4
On the basis of these data, active screening for
myocarditis of patients who receive ICPis has been
proposed by measuring cardiac troponin (cTn), es-
pecially during the ﬁrst weeks of treatment when most
cases of ICPi-associated myocarditis seem to occur.2,6
This recommendation aims at further improving the
early detection of myocarditis and prompting its ap-
propriate management to forestall a potentially lethal
evolution. Nonetheless, it also promotes extensive cTn
testing, which may not be sustainable unless some
concepts, well known by the cardiologist but not
necessarily familiar to the oncologist, are kept in mind.
What cTn Measures and What Elevated Levels Mean
Both isoforms of cTn, cTnI and cTnT, are components
of the contractile apparatus of cardiomyocytes. When
cardiomyocytes are damaged, they are released
into the extracellular space and eventually into the
bloodstream.7 Noncardiac tissues do not normally
express cTn, which is thereby cardiac speciﬁc. Nev-
ertheless, a number of conditions that affect the heart
lead to cTn concentrations above the upper reference
limit (URL).7
Among cardiac diseases that underlie a rise in cTn,
acute coronary syndrome (ACS) is themost frequent. It
may be the consequence of sudden coronary artery
obstruction, typically by a thrombus that has grown at
the surface of an atherosclerotic plaque.8 ACS also
may result from an imbalance between myocardial
oxygen demand and blood supply, with the latter not
increasing proportionally with the former; this most
often happens because of preexisting coronary lesions
that have narrowed the artery lumen and limit blood
ﬂow.8 Noncardiac disorders, such as chronic kidney
disease or pneumonia, also may directly or indirectly
elicit myocardial injury. In fact, the cause of increased
cTn levels in hospitalized patients is most frequently
noncardiac or multifactorial.9
Germane to the surveillance of patients who receive
ICPis, cTnT may no longer be cardiac speciﬁc in the
presence of skeletal muscle disorders. In this context,
elevated concentrations of cTnT were demonstrated
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despite normal heart structure and function possibly be-
cause commercial assays detect Tn isoforms expressed by
the diseased muscle.10 Because myositis is an emerging
immune-related AE of ICPis,11 this possibility should not be
overlooked. Likewise, mild elevations in cTn may be the
result of inﬂammation of the subepicardial myocardium
during pericarditis.4 This is important in view of the evi-
dence that pericarditis is another immune-related AE of
ICPis.4 Finally, circulating cTn is measurable in a sub-
stantial proportion of healthy individuals by current high-
sensitivity assays,13 with this indeed being the reason why
the cutoff for abnormal values is set to above the 99th
percentile of the URL.
With this background, cTn testing will help to diagnosis and
support therapeutic choices only if it is related to the clinical
context. Assessment of cTn levels regardless of the clinical
scenario rarely provides clear-cut indications for changing
and improving patient management.7 Conversely, cTn
measurement may give prognostic information irrespective
of the clinical situation because increased cTn values are
associated with worse outcomes and higher mortality in the
general population14 and in patients with both cardiac and
noncardiac conditions.7,9
Troponin Testing for ICPi-Associated Myocarditis
The aforementioned considerations hold true for ICPi-related
myocarditis. In general, endomyocardial biopsy is the gold
standard to diagnose myocarditis.15 Being an invasive pro-
cedure, however, it is performed only when indicated by
a work-up that includes clinical examination, ECG, bio-
chemicalmarkers ofmyocardial injury as well of inﬂammation,
echocardiography, and cardiac magnetic resonance.15 This
latter imaging technique is now capable of revealing myo-
cardial inﬂammation with high accuracy to the point that
endomyocardial biopsy often becomes unnecessary to reach
the diagnosis of myocarditis and begin therapy.12 Thus,
comprehensive evaluation of a patient with suspected ICPi-
triggered myocarditis is of utmost importance.
Alarming symptoms and signs, such as new-onset or
worsening fatigue, chest pain, dyspnea, palpitation, pe-
ripheral edema, or hypotension, should be noted imme-
diately and prompt an accurate clinical evaluation.5 A
deﬁnite diagnosis of myocarditis relies on consistent
symptoms and signs together with one or more of the
following: newly abnormal ECG, cTn elevation, or new and
otherwise unexplained functional and structural alterations
on cardiac imaging.15 Consultation with a cardiologist is
fundamental.16,17 However, the results of ECG and cTn
testing may precede the cardiologist’s evaluation and have
to be interpreted by the physician who is administering the
ICPi, at least preliminarily. Any signiﬁcant modiﬁcation of
the ECG should prompt the suspicion of an ongoing cardiac
(or pericardial) disease. As far as cTn is concerned, we
propose the following guiding points. First, an increase in
cTn may indicate not only myocarditis but also myocardial
injury as a result of other causes. Second, in particular, the
possibility of ACS, which is far more common than myo-
carditis, must be taken into account; mildly elevated cTn
also may be a feature of pericarditis. Third, ACS especially
should be considered in cases of major cardiovascular risk
factors, family history of ischemic heart disease at a young
age, typical chest pain, and ECG changes limited to some
leads that explore a deﬁnite region of the left ventricle.
Fourth, a ﬁrst abnormal cTn concentration must be fol-
lowed by retesting (after 2 to 3 hours if a high-sensitivity
assay is used) to determine the dynamics of cTn elevation;
ACS is characterized by a typical rising and/or falling pattern
of cTn values (v persistently increased values in myocar-
ditis).8 Finally, cTn levels may be normal initially in myo-
carditis18; if the clinical suspicion is high, ECG, cTn, and
echocardiography should be repeated after 1 or a few days
and be vigilant meanwhile.
In summary, measurement of cTn upon the appearance of
suggestive cardiac symptoms and signs is appropriate and
consistent with the state-of-the-art approach to any myo-
carditis (Fig 1A). The only caveat is to read the results of the
test correctly. The level of alarm must be high in the
suspicion of myocarditis, and direct referral to an emer-
gency department may be appropriate.
By contrast, the issue of whether cTn should be routinely
assessed in asymptomatic patients receiving ICPis is un-
resolved. ASCO suggests consideration of baseline cTn de-
terminations, especially in patients who are receiving
combination immune therapy, because a basal value of cTn
may be helpful in cases of subsequent unclear symptoms or
equivocal diagnostic examinations.16 No indication is provided
about serial cTn measurements because of the lack of
supporting evidence. Similarly, the Toxicity Management
Working Group of the Society for Immunotherapy of Cancer
recommends cTn assessment at baseline while highlighting
the uncertainty about the cost effectiveness of repeated cTn
testing given the rarity of ICPi-associated myocarditis and the
paucity of available data.17 Of note, the working group also
states that an accurate cardiovascular evaluation should be
done before initiating ICPis, with participation of a cardiologist
if needed.17 This pretreatment visit is invaluable because it
provides information that may allow for better management of
subsequent cardiovascular events. For example, estimation of
the likelihood of ACS will be more accurate if the cardio-
vascular risk factor proﬁle is known. Moreover, having a basal
ECG is prerequisite for analyzing any change during therapy.
Some expert centers systematically measure cTn at regular in-
tervals during the ﬁrst weeks of combination immunotherapy.2,6
This strategy is motivated by the fact that myocarditis is more
frequent and severe with dual thanwith single ICPi treatment
and may be fatal; thus, it must be looked for irrespectively of
the clinical scenario. It is also based on the assumption that
most of the time, an increase in cTn during ICPi therapy
corresponds to some degree of myocarditis, as it does the
elevation in cTn that accompanies typical symptoms, evident
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ECG alterations, and consistent ﬁndings on imaging. Al-
though anecdotal reports suggest that ICPi-related myo-
carditis may present with isolated abnormal cTn,18 this is
not what usually happens according to the published
experience.2-4 This also is not the case with myocarditis in
general for which two or more criteria (signiﬁcant changes in
cTn, ECG, or imaging) are requested for the clinical diagnosis
if the patient is asymptomatic.15 In the absence of a sug-
gestive clinical picture, myocarditis is a rarer cause of cTn
elevation than, for instance, ACS or noncardiac disease,
even in patients who receive two ICPis (Fig 1B). This concept
has practical implications. Currently, it is advised to hold
Other possible causes for asymptomatic
increase in cTn are more likely 
There may be other possible causes for
asymptomatic increase in cTn
          ICPi monotherapy
and elevated cTn
but no clinical suspicion of myocarditis
Total positive cTn tests Myocarditis
C
Total positive cTn tests
          ICPi combination therapy
and elevated cTn
but no clinical suspicion of myocarditis
Myocarditis
B
Total positive cTn tests Myocarditis
A
         ICPi therapy
and elevated cTn
and clinical suspicion of myocarditis
consider other causes for the patient’s
presentation and the increase in cTn
(ACS, non-cardiac diseases)
FIG 1. Diverse value of positive cardiac troponin (cTn) testing in patients who receive immune checkpoint inhibitor
(ICPi) therapy with various clinical presentations. (A) A clinical scenario suggestive for myocarditis that complicates
treatment with ICPis in which cTn is elevated. Especially if other causes of increased cTn are reasonably excluded,
such as acute coronary syndrome (ACS) and noncardiac disorders, the high cTn concentration will reﬂect an ongoing
myocarditis in the majority of all tested patients (red and blue circles, respectively). (B) The situation where cTn is
assessed in patients who receive combination immune therapy but without any clinical clues of myocarditis. Because
dual ICPi treatment is particularly associated with the risk of developing myocarditis, there will be patients with
elevated cTn levels who have asymptomatic or atypical myocardial inﬂammation. However, the increase in cTn may
be caused by many other conditions, which would be incorrectly diagnosed as myocarditis on the sole result of cTn
testing. Note that even healthy individuals who face cardiac stress (eg, after intense exercise) may have cTn
concentrations above the upper reference limit with modern high-sensitivity assays. (C) On-treatment surveillance of
patients who receive a single ICPi. The proportion of patients with high cTn and clinically silent or atypical myocarditis
will be lower than shown in (B) because the risk of myocarditis with single-drug immune therapy is smaller than with
combination treatment. By contrast, other conditions will prevail as the actual cause of cTn elevation. The size of the
circles that identify total positive and myocarditis cases is arbitrary. Atypical indicates a myocarditis with uncommon
presentation, which may be difﬁcult to recognize even for the specialist (eg, isolated nausea, fever).
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ICPis for any-grade toxicity, including modiﬁcations of car-
diac biomarkers, and to permanently discontinue them in
case of evenmild symptoms.16 However, because symptoms
may be attributed tomyocarditis despite being of other origin,
a substantial risk of abandoning immunotherapy un-
necessarily exists.
Systematic cTn testing also has been suggested during ICPi
monotherapy.19 Here, the sensitivity of such a screening is
expected to be even lower because myocarditis induced by
single ICPi treatment is less frequent than by treatment with
two ICPis4 (Fig 1C). As on-treatment surveillance approach
with serial cTn determination, we measured cTnI levels in
59 patients treated with nivolumab for non–small-cell lung
cancer, the majority of whom did not have a history of
cardiovascular disease, diabetes, or chronic kidney dis-
ease.20 One patient had a cTnI value above the URL and
another six showed an increased concentration during treat-
ment, all without overt cardiovascular events. Yet, only one
patient was deemed as possibly having subclinical myocarditis
upon cardiologic evaluation by the cardio-oncologist, with the
others ascribed to myocardial ischemia secondary to a mis-
match between oxygen demand and supply.20
Conclusion
Major concerns exist about assessing cTn to detect
asymptomatic myocarditis during ICPi treatment. Dedicated
prospective studies are needed, with a particular focus
on patients at higher risk, such as those prescribed
combination immune therapy. ECG is widespread and
easily readable, but it is neither sensitive nor speciﬁc
enough for myocarditis screening. The role of other
biomarkers or imaging techniques, if any, is still to be
investigated. What should be done then? With the
watchful awareness about the possibility of ICPi-
triggered myocarditis, all diagnostic tests, including
cTn, should be used wisely and guided by clinical rea-
soning. Intense interaction between the oncologist and
cardio-oncologist (or cardiologist) is crucial.
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